Novo Nordisk Stock Plummets: Bearish Signals Dominate After Drug Trial Miss

Novo Nordisk A/S NVO is seeing its stock spiral downwards, with shares plummeting 20% early Friday following the release of Phase 3 trial data.

While the headlines point to a new trial result that failed to meet expectations, the technical analysis reveals a deeper, more concerning picture of the stock’s momentum.

Read News Details: Novo Nordisk’s Hybrid Weight Loss Drug Falls Short On Expectations, Stock Plunges

Chart created using Benzinga Pro

NVO Stock Has Bearish Signals Across The Board

NVO's charts are filled with clear signs of weakness, and the technicals are currently dominated by bearish trends.

Here’s a breakdown of what the indicators are signaling:

• Exponential Moving Averages (EMAs): NVO stock is trading below its five, 20, and 50-day EMAs, marking a distinct downtrend. A sustained move below these averages generally indicates a lack of bullish momentum and suggests further downside potential in the near term.
• Simple Moving Averages (SMAs): Novo Nordisk's stock price of $82.70 is significantly below its eight-day simple moving average (SMA) of $104.43, 20-day SMA of $106.54 and 50-day SMA of $109.23. With all these moving averages acting as resistance levels, the bearish sentiment remains entrenched. Furthermore, the price is well below the 200-day SMA of $126.23, reinforcing the ongoing downtrend.
• MACD (Moving Average Convergence Divergence): The MACD reading of a negative 2.68 is a clear sign of negative momentum. A negative MACD indicates that the short-term moving averages are below the long-term averages, further validating the lack of bullish pressure and signaling that the stock could remain under selling pressure.
• RSI (Relative Strength Index): NVO's RSI is currently at 18.58, a deeply oversold level. While this could suggest that the stock is due for a short-term bounce, it also points to how overextended NVO stock has become to the downside. Historically, an RSI this low can signal that a reversal is due, but with the broader trend still bearish, any bounce might be short-lived and met with renewed selling.

For now, NVO stock is in a strong technical downtrend, with little immediate indication that it will break free from the selling pressure.

Read Next:

• US Steel Issues Weak Q4 Outlook, Joins Novo Nordisk And Other Big Stocks Moving Lower In Friday’s Pre-Market Session

Photo: Shutterstock